Shilpa Medicare launches generic verision cancer drug Dasatinib at monthly therapy cost of Rs 6,440

The branded generic anti-cancer drug will be available in all dosage strengths of 20/ 50/ 70/ 100 mg tablets

Published On 2020-04-25 07:14 GMT   |   Update On 2020-04-25 07:14 GMT
Advertisement

New Delhi: Shilpa Medicare on Friday said it has launched its generic version of cancer drug  generat a monthly therapy cost of Rs 6,440.

The drug substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on 12 April 12, 2020. The current monthly therapy cost of innovator is approximately Rs 1.65 lakh, Shilpa Medicare said in a regulatory filing.

Shilpa Medicare has launched the Indian branded generic of Dasatinib, an anti-cancer drug with a brand name Dasashil, it added.

Advertisement

The branded generic anti-cancer drug will be available in all dosage strengths of 20/ 50/ 70/ 100 mg tablets. It is used for the treatment of Chronic Myeloid Leukaemia (CML), the company said.

"Dasashil will revolutionize the treatment by ensuring to make therapy available for more Indian patients due to increased affordability," Shilpa Medicare claimed.

The products are being manufactured and supplied from the company's US Food and Drug Administration-approved manufacturing facility, it added.

"Today there are around 10,000 to 15,000 new patients of CML in India, which can be benefited by Dasashil tablets," the company.

Shilpa Medicare Limited (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka- India.

The commercial production in the SML was started in November 1989.

Read also: Shilpa Medicare gets USFDA EIR for Raichur API Unit

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News